MedTrace Logo

A Phase I Study of SB Cell for the Enhanced Osseointegration of Guided Bone Regeneration in Implant Surgery

NCT04451486 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-06-30

No results posted yet for this study

Summary

This is a Phase 1 study to evaluate the safety profile of autologous-derived SB cells to enhance osseointegration of GBR in patients undergoing dental implant surgery.

Conditions

  • Guided Bone Regeneration

Interventions

DRUG

SB cells

1x10\*5 CD61-Lin- cells /0.25mL DPBS

DRUG

SB cells

1x10\*6 CD61-Lin- cells /0.25mL DPBS

DRUG

SB cells

1x10\*7 CD61-Lin- cells /0.25mL DPBS

Sponsors & Collaborators

  • Taipei Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-10
Primary Completion
2019-12-12
Completion
2021-04-25

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451486 on ClinicalTrials.gov